HPLC Quantification and Stability Study of Antilipidemic Polyherbal Formulation
DOI:
https://doi.org/10.18311/jnr/2022/29013Keywords:
Hyperlipidaemia, HPLC Quantification, Polyherbal Formulation, Shelf-life StudyAbstract
Hyperlipidemia is one of the major risk factor for cardio vascular disorders, which accounts for the one third of total death in the world. In the present study an Antilipidemic polyherbal formulation was prepared and contains four herbal drugs namely Murraya koenigi leaves, Acacia catechu bark, Emblica officinalis fruits and leaves of Gymnema sylvestra. The study involved HPLC marker-based quantification and shelf-life evaluation of a traditional Antilipidemic formulation. The quantification method for the biomarkers present in the polyherbal formulation was developed using reverse phase method by using shim-pack HPLC C18 column (250 X 4.6 mm, 5 ?m). The four phytoconstituents selected for the study are mahanine, quercetin, gallic acid and gymnemic acid respectively. The percentage content of quercetin, gallic acid, gymnemic acid and mahanine in the PHF was found to be 0.82%w/w,10.15%w/w, 2.77%w/w and 14.19%w/w respectively. Shelf life is an important component that is mandatory to be displayed on the label of all medicinal products. This is also applicable to Ayurveda. The shelf life of polyherbal formulations is also assessed in this study using an accelerated stability analysis. At a temperature of 40.2 °C and a relative humidity of 75%, physicochemical parameters were measured. The analysis was repeated at 1, 3, and 6-month intervals, with the average 10% deterioration time calculated and extrapolated to determine the shelf life. It was found that the shelf life of formulated Antilipidemic polyherbal formulation was 2 years 2 months. The polyherbal formulation prepared and evaluated can be effectively used for the treatment of hyperlipidemia and the preparation can be used without any deterioration for a period of 2 years.Downloads
Metrics
Downloads
Published
How to Cite
Issue
Section
Accepted 2022-04-29
Published 2022-07-30
References
Shrikar KD, Ashpak MT. Review on concept and scope of polyherbal formulations. Int J Innov Res Technol Sci. 2020; 7(1):282–8.
Zodda D, Giammona R, Schiilliti, S. Treatment strategy for dyslipidemia in cardiovascular disease prevention: Focus on old and new drugs. Pharmacy. 2018; 6:10–10. https://doi.org/10.3390/pharmacy6010010. PMid:29361723. PMCid:PMC5874549 DOI: https://doi.org/10.3390/pharmacy6010010
Aslam MS, Ahmad MS, Mamat AS, Ahmad MZ, Salam F. An update review on polyherbal formulation: A global perspective. Syst Rev Pharm. 2016; 7(1):35–41. https://doi.org/10.5530/srp.2016.7.5 DOI: https://doi.org/10.5530/srp.2016.7.5
Kshirsagar RR, Vaidya SA, Jain V. Development and validation of a novel RP-HPLC method for the simultaneous quantification of ascorbic acid, gallic acid, ferulic acid, piperine, and thymol in a polyherbal formulation. Indian J Nat Prod Resour. 2020; 11(4):307–11.
Sawant L, Prabhakar B, Pandita N. Quantitative HPLC analysis of ascorbic acid and gallic acid in Phyllanthus emblica. J Anal Bioanal Tech. 2010; 1(2):111–14. https://doi.org/10.4172/2155-9872.1000111 DOI: https://doi.org/10.4172/2155-9872.1000111
Goyal C, Khemchand S, Kumar GA. Stability testing of ayurvedic formulations: Exigency of today’s world. Int J Green Pharm. 2017; 11(3):338–42.
Bhagwat GB, Kadam SS, Hivarale M. The accelerated stability study of constalax churna – An ayurvedic formulation. Int J Ayurveda Res. 2017; 5(7):85–90.
Patgiri B, Soni H, Bhatt S. Evaluation of stability study of Ayurvedic formulation – Rasayana Churna. J Pharmacogn Phytochem. 2014; 2:126–30.
Sachan AK, Kumar A. Stability testing of herbal products. J Chem Pharm Res. 2015; 7(12):511–14.
Heneczkowski M, Kopacz M, Nowak D, Kuzniar A. Infrared spectrum analysis of some flavonoids. Acta Pol Pharm. 2001; 58:415–20.
Anonymous. The ayurvedic pharmacopoeia of India. Government of India: Ministry of Health and Family Welfare; Part I. Appendix-3; 2007.
Grimm W. Extension of the international conference on harmonization tripartite guideline for stability testing of new drug substances and products to countries of climatic zones III and IV. Drug Dev Ind Pharm. 1998; 24:313–25. https://doi.org/10.3109/03639049809085626. PMid:9876591 DOI: https://doi.org/10.3109/03639049809085626